CLOVIS ONCOLOGY INC's ticker is and the CUSIP is 189464AC4. A total of 16 filers reported holding CLOVIS ONCOLOGY INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $1,823,000 | -37.1% | 2,500,000 | -35.9% | 0.00% | -50.0% |
| Q2 2021 | $2,898,000 | -1.7% | 3,900,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $2,947,000 | +6.2% | 3,900,000 | -2.5% | 0.00% | +100.0% |
| Q4 2020 | $2,774,000 | -0.9% | 4,000,000 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $2,800,000 | +84.9% | 4,000,000 | +60.0% | 0.00% | +100.0% |
| Q2 2020 | $1,514,000 | -48.8% | 2,500,000 | -50.0% | 0.00% | -66.7% |
| Q1 2020 | $2,955,000 | -5.8% | 5,000,000 | 0.0% | 0.00% | +50.0% |
| Q4 2019 | $3,138,000 | -21.4% | 5,000,000 | -47.7% | 0.00% | -33.3% |
| Q3 2019 | $3,992,000 | -32.8% | 9,553,000 | 0.0% | 0.00% | -40.0% |
| Q2 2019 | $5,943,000 | -10.9% | 9,553,000 | +11.7% | 0.01% | -16.7% |
| Q1 2019 | $6,670,000 | -15.3% | 8,553,000 | -24.0% | 0.01% | -25.0% |
| Q4 2018 | $7,875,000 | -23.3% | 11,253,000 | -15.3% | 0.01% | -11.1% |
| Q3 2018 | $10,264,000 | -8.5% | 13,278,000 | +9.1% | 0.01% | -18.2% |
| Q2 2018 | $11,212,000 | – | 12,175,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Jabre Capital Partners S.A. | 3,500,000 | $2,732,000 | 0.90% |
| SHENKMAN CAPITAL MANAGEMENT INC | 8,721,000 | $6,769,000 | 0.82% |
| CAMDEN ASSET MANAGEMENT L P /CA | 32,275,000 | $24,949,000 | 0.70% |
| PFM Health Sciences, LP | 57,632,000 | $44,730,000 | 0.66% |
| Partner Investment Management, L.P. | 768,000 | $596,000 | 0.46% |
| SYMPHONY ASSET MANAGEMENT LLC | 1,000,000 | $776,000 | 0.21% |
| SSI INVESTMENT MANAGEMENT LLC | 3,000,000 | $2,319,000 | 0.18% |
| PointState Capital LP | 12,000,000 | $9,342,000 | 0.12% |
| MIZUHO SECURITIES USA LLC | 2,000,000 | $1,548,000 | 0.12% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 2,000,000 | $1,546,000 | 0.11% |